Profusa

Executive Summary

Profusa is a San Francisco-based biotechnology company pioneering tissue-integrated, injectable biosensors for continuous, real-time monitoring of body chemistry. Its proprietary Lumee™ platform utilizes biocompatible hydrogel microsensors that are injected into the body and provide clinical-grade data on key analytes such as oxygen and glucose over extended periods. Founded in 2008, Profusa aims to transform chronic disease management by enabling persistent, autonomous sensing that eliminates the need for frequent finger sticks or invasive tests. The technology holds promise for applications in diabetes management and critical limb ischemia, offering the potential for early detection of metabolic disturbances and improved therapeutic interventions.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation for Lumee™ Oxygen Sensor in Critical Limb Ischemia70% success
• Q2 2027Completion of Pivotal Clinical Trial for Glucose Monitoring60% success
• Q4 2026Strategic Partnership with Major Diabetes Device Company55% success